Table V.

T-cell therapy with the use of third-party CTL for viral infections after stem cell transplant.

Reference	n	Target	Type of HSCT	Serious Adverse Events	Results
Barker, 2010 (56) and Doubrovina, 2012 (42)	5	EBV	Cord blood	None	➢4 patients achieved CR ➢1 patient had disease progression
Uhlin, 2010 (61)	1	EBV	Cord blood	None	➢CR ➢Subsequent relapse treated with 2nd CTL infusion
Leen, 2010 (62) and Leen, 2012 (63)	44	EBV, CMV, AdV	MRD, MUD, cord blood	➢8 cases of GvHD after CTL (2 cases of de novo GvHD and 6 cases of GvHD recurrence)	➢82% CR and partial remission
Qasim, 2011 (57)	1	Adv	MMUD	Grade II-IV GvHD (skin, liver)	➢AdV clearance ➢Patient died of CMV pneumonia